Treatment outcomes among a cohort of African American buprenorphine patients: Follow-up at 12 months

References

• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;(2):CD002207.
   PubMed Web of Science ®Google Scholar
• Hser YI, Evans E, Huang D, Weiss R, Saxon A, Carroll KM, Woody G, Liu D, Wakim P, Matthews AG, et al. Long-term outcomes after randomization to buprenorphine/naloxone versus methadone in a multi-site trial. Addiction. 2016;111(4):695–705. doi:10.1111/add.13238.
   PubMed Web of Science ®Google Scholar
• Giacomuzzi SM, Riemer Y, Ertl M, Kemmler G, Rossler H, Hinterhuber H, Kurz M. Buprenorphine versus methadone maintenance treatment in an ambulant setting: a health-related quality of life assessment. Addiction. 2003;98(5):693–702. doi:10.1046/j.1360-0443.2003.00352.x.
   PubMed Web of Science ®Google Scholar
• Ponizovsky AM, Grinshpoon A. Quality of life among heroin users on buprenorphine versus methadone maintenance. Am J Drug Alcohol Abuse. 2007;33(5):631–42. doi:10.1080/00952990701523698.
   PubMed Web of Science ®Google Scholar
• Fiellin DA, Moore BA, Sullivan LE, Becker WC, Pantalon MV, Chawarski MC, Barry DT, O’Connor PG, Schottenfeld RS. Long-term treatment with buprenorphine/naloxone in primary care: results at 2-5 years. Am J Addict. 2008;17(2):116–20.
   PubMed Web of Science ®Google Scholar
• Haddad MS, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: real-world substance abuse treatment outcomes. Drug Alcohol Depend. 2013;131(1–2):127–35. doi:10.1016/j.drugalcdep.2012.12.008.
   PubMed Web of Science ®Google Scholar
• Riggins DP, Cunningham CO, Ning Y, Fox AD. Recent incarceration and buprenorphine maintenance treatment outcomes among human immunodeficiency virus-positive patients. Subst Abuse. 2017;38(3):297–302.
   Web of Science ®Google Scholar
• Soeffing JM, Martin LD, Fingerhood MI, Jasinski DR, Rastegar DA. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year. J Subst Abuse Treat. 2009;37(4):426–30. doi:10.1016/j.jsat.2009.05.003.
   PubMed Web of Science ®Google Scholar
• Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Boticelli M, Samet JH. Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Arch Intern Med. 2011;171(5):425–31. doi:10.1001/archinternmed.2010.541.
   PubMedGoogle Scholar
• Parran TV, Adelman CA, Merkin B, Pagano ME, Defranco R, Ionescu RA, Mace AG. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106(1):56–60. doi:10.1016/j.drugalcdep.2009.07.013.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Potter JS, Griffin ML, Provost SE, Fitzmaurice GM, McDermott KA, Srisarajivakul EN, Dodd DR, Dreifuss JA, McHugh RK, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend. 2015;150:112–19. doi:10.1016/j.drugalcdep.2015.02.030.
   PubMed Web of Science ®Google Scholar
• Finch JW, Kamien JB, Amass L. Two-year experience with Buprenorphine-naloxone (Suboxone) for maintenance treatment of opioid dependence within a private practice setting. J Addict Med. 2007;1(2):104–10. doi:10.1097/ADM.0b013e31809b5df2.
   PubMed Web of Science ®Google Scholar
• Miotto K, Hillhouse M, Donovick R, Cunningham-Rathner J, Charuvastra C, Torrington M, Esagoff AE, Ling W. Comparison of buprenorphine treatment for opioid dependence in 3 settings. J Addict Med. 2012;6(1):68–76. doi:10.1097/ADM.0b013e318233d621.
   PubMed Web of Science ®Google Scholar
• Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. National survey of substance abuse treatment services (N-SSATS). Rockville, MD: SAMHSA; 2004-2014.
   Google Scholar
• Center for Disease Control and Prevention. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. http://wonder.cdc.gov.
   Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend. 2013;128(3):222–29. doi:10.1016/j.drugalcdep.2012.08.027.
   PubMed Web of Science ®Google Scholar
• McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M. The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992;9(3):199–213. doi:10.1016/0740-5472(92)90062-S.
   PubMed Web of Science ®Google Scholar
• Chand PK, Mattoo SK, Sharan P. Quality of life and its correlates in patients with bipolar disorder stabilized on lithium prophylaxis. Psychiatry Clin Neurosci. 2004;58(3):311–18. doi:10.1111/pcn.2004.58.issue-3.
   PubMed Web of Science ®Google Scholar
• Group W. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28(3):551–58. doi:10.1017/S0033291798006667.
   PubMed Web of Science ®Google Scholar
• Hawthorne G, Herrman H, Murphy B. Interpreting the WHOQOL-BREF: preliminary population norms and effect sizes. Soc Indic Res. 2006;77:37–59. doi:10.1007/s11205-005-5552-1.
   Web of Science ®Google Scholar
• Noerholm V, Groenvold M, Watt T, Bjorner JB, Rasmussen NA, Bech P. Quality of life in the Danish general population–normative data and validity of WHOQOL-BREF using Rasch and item response theory models. Qual Life Res. 2004;13(2):531–40. doi:10.1023/B:QURE.0000018485.05372.d6.
   PubMed Web of Science ®Google Scholar
• World Health Organization. The World Health Organization Quality of Life (WHOQOL) - Bref. Geneva, Switzerland: WHO; 2004.
   Google Scholar
• O’Carroll RE, Smith K, Couston M, Cossar JA, Hayes PC. A comparison of the WHOQOL-100 and the WHOQOL-BREF in detecting change in quality of life following liver transplantation. Qual Life Res. 2000;9(1):121–24. doi:10.1023/A:1008901320492.
   PubMed Web of Science ®Google Scholar
• Skevington SM, Lotfy M, O’Connell KA, Group W. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Qual Life Res. 2004;13(2):299–310. doi:10.1023/B:QURE.0000018486.91360.00.
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addiction. 2012;107(5):943–52. doi:10.1111/j.1360-0443.2011.03700.x. PMCID: PMC3319854.
   PubMed Web of Science ®Google Scholar
• Weiss RD, Griffin ML, Potter JS, Dodd DR, Dreifuss JA, Connery HS, Carroll KM. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management? Drug Alcohol Depend. 2014 Jul;1(140):118–22. doi:10.1016/j.drugalcdep.2014.04.005.
   Google Scholar
• Stoller KB, Stephens MC, Schorr A. Integrated service delivery models for opioid treatment programs in an era of increasing opioid addiction, health reform, and party. Baltimore, MD: American Association for the Treatment of Opioid Dependence; 2016.
   Google Scholar
• Mitchell SG, Gryczynski J, Schwartz RP, Myers CP, O’Grady KE, Olsen YK, Jaffe JH. Changes in quality of life following buprenorphine treatment: relationship with treatment retention and illicit opioid use. J Psychoactive Drugs. 2015;47(2):149–57. doi:10.1080/02791072.2015.1014948.
   PubMed Web of Science ®Google Scholar
• Kelly E, Fulginiti A, Pahwa R, Tallen L, Duan L, Brekke JS. A pilot test of a peer navigator intervention for improving the health of individuals with serious mental illness. Community Ment Health J. 2014;50:435. doi:10.1007/s10597-013-9616-4.
   PubMed Web of Science ®Google Scholar